United Therapeutics Co. (UTHR) Receives Average Rating of “Hold” from Analysts

Shares of United Therapeutics Co. (NASDAQ:UTHR) have been assigned an average recommendation of “Hold” from the fifteen analysts that are presently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $140.27.

UTHR has been the subject of a number of research analyst reports. ValuEngine raised shares of United Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Zacks Investment Research cut shares of United Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 3rd. TheStreet cut shares of United Therapeutics from a “b-” rating to a “c” rating in a research report on Friday, September 29th. HC Wainwright reaffirmed a “hold” rating and set a $95.00 price objective on shares of United Therapeutics in a research report on Thursday, October 26th. Finally, Cowen reaffirmed a “hold” rating and set a $129.00 price objective on shares of United Therapeutics in a research report on Friday, October 27th.

In other United Therapeutics news, CEO Martine A. Rothblatt sold 1,241 shares of the stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $128.95, for a total transaction of $160,026.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Christopher Causey sold 580 shares of the stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $134.72, for a total transaction of $78,137.60. Following the sale, the director now owns 1,555 shares in the company, valued at $209,489.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,508 shares of company stock worth $1,774,621. 7.80% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the business. KBC Group NV lifted its holdings in United Therapeutics by 3.5% during the 3rd quarter. KBC Group NV now owns 22,974 shares of the biotechnology company’s stock worth $2,692,000 after buying an additional 783 shares in the last quarter. Swiss National Bank raised its holdings in shares of United Therapeutics by 1.0% in the 3rd quarter. Swiss National Bank now owns 165,600 shares of the biotechnology company’s stock valued at $19,407,000 after purchasing an additional 1,600 shares in the last quarter. California Public Employees Retirement System raised its holdings in shares of United Therapeutics by 1.5% in the 3rd quarter. California Public Employees Retirement System now owns 133,793 shares of the biotechnology company’s stock valued at $15,679,000 after purchasing an additional 1,993 shares in the last quarter. FMR LLC raised its holdings in shares of United Therapeutics by 2.8% in the 2nd quarter. FMR LLC now owns 4,254,841 shares of the biotechnology company’s stock valued at $551,980,000 after purchasing an additional 116,062 shares in the last quarter. Finally, Van ECK Associates Corp raised its holdings in shares of United Therapeutics by 9.4% in the 3rd quarter. Van ECK Associates Corp now owns 123,100 shares of the biotechnology company’s stock valued at $14,426,000 after purchasing an additional 10,598 shares in the last quarter.

United Therapeutics (NASDAQ:UTHR) traded down $0.02 during trading on Friday, hitting $139.51. 463,591 shares of the stock traded hands, compared to its average volume of 426,346. United Therapeutics has a twelve month low of $112.01 and a twelve month high of $169.89. The stock has a market cap of $6,030.00, a PE ratio of 12.30 and a beta of 1.41.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.01 by $2.26. The firm had revenue of $445.50 million during the quarter, compared to analysts’ expectations of $426.43 million. United Therapeutics had a net margin of 30.50% and a return on equity of 26.24%. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter last year, the company posted $4.23 EPS. analysts forecast that United Therapeutics will post 12.96 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “United Therapeutics Co. (UTHR) Receives Average Rating of “Hold” from Analysts” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/19/united-therapeutics-co-uthr-receives-average-rating-of-hold-from-analysts.html.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply